Adverum Biotechnologies Inc. (ADVM)’s Financial Results Comparing With Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

As Biotechnology companies, Adverum Biotechnologies Inc. (NASDAQ:ADVM) and Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) are our subject to compare. And more specifically their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adverum Biotechnologies Inc. 8 586.94 N/A -1.12 0.00
Verrica Pharmaceuticals Inc. 11 0.00 N/A -1.03 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Adverum Biotechnologies Inc. and Verrica Pharmaceuticals Inc.

Profitability

Table 2 shows us Adverum Biotechnologies Inc. and Verrica Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Adverum Biotechnologies Inc. 0.00% -33.4% -30.8%
Verrica Pharmaceuticals Inc. 0.00% -28.4% -27.5%

Liquidity

The Current Ratio and Quick Ratio of Adverum Biotechnologies Inc. are 18.2 and 18.2 respectively. Its competitor Verrica Pharmaceuticals Inc.’s Current Ratio is 27.7 and its Quick Ratio is 27.7. Verrica Pharmaceuticals Inc. can pay off short and long-term obligations better than Adverum Biotechnologies Inc.

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Adverum Biotechnologies Inc. and Verrica Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Adverum Biotechnologies Inc. 0 0 0 0.00
Verrica Pharmaceuticals Inc. 0 0 1 3.00

Verrica Pharmaceuticals Inc. on the other hand boasts of a $20 average target price and a 89.93% potential upside.

Institutional and Insider Ownership

Roughly 76% of Adverum Biotechnologies Inc. shares are owned by institutional investors while 34.9% of Verrica Pharmaceuticals Inc. are owned by institutional investors. Insiders owned 11.22% of Adverum Biotechnologies Inc. shares. Insiders Comparatively, owned 10.2% of Verrica Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Adverum Biotechnologies Inc. -8.28% 15.9% 106.94% 342.57% 185.32% 325.71%
Verrica Pharmaceuticals Inc. 19.18% -0.16% 24.9% 1.92% -30.45% 50.18%

For the past year Adverum Biotechnologies Inc.’s stock price has bigger growth than Verrica Pharmaceuticals Inc.

Summary

Verrica Pharmaceuticals Inc. beats Adverum Biotechnologies Inc. on 6 of the 8 factors.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has a pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT. The company is also developing ADVM-053 to treat hereditary angioedema; and other product candidates, such as ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is headquartered in West Chester, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.